Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.68 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23898746 | 1.00 | DPP4 (0.68) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL30017660 | 1.00 | DPP4 (0.68) | DPP4F2HTR2ATAAR1ADRA2A | |
| Hydrochloric Acid SCHEMBL25181392 | 0.97 | DPP4 (0.65) | DPP4F2HTR2ATAAR1ADRA2A | |
| Hydrochloric Acid SCHEMBL25204642 | 0.97 | DPP4 (0.65) | DPP4F2HTR2ATAAR1ADRA2A | |
| Hydrochloric Acid SCHEMBL25181393 | 0.97 | DPP4 (0.65) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL3957345 | 0.84 | DPP4 (0.62) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL1878642 | 0.82 | DPP4 (1.00) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL239938 | 0.82 | DPP4 (1.00) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL644767 | 0.82 | DPP4 (1.00) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL2067094 | 0.82 | DPP4 (1.00) | DPP4F2HTR2ATAAR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2532663-B1 | Naphthalenetetracarboxylic acid derivatives and their use as semiconductors | BASF SE (DE) | 2016-03-16 | — | — | EP | claimed |
| EP-2532663-A1 | Naphthalenecarboxylic acid derivatives and their use as semiconductors | BASF SE (DE) | 2012-12-12 | — | — | EP | claimed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| EP-4126848-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| US-11548871-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| CN-115380030-A | N-heteroarylalkyl-2- (heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2022-11-22 | — | — | CN | disclosed |
| US-20220324865-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-10-13 | — | — | US | disclosed |
| EP-1888563-A1 | PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20080017850-A1 | applying n-type organic semiconducting compound 1,6,7,12-Tetrachloro-N,N'-benzyl-perylene-3,9; 11,12-tetracarboxylic diimide or 1,6,7,12-tetrachloroperylen-3,9; 9,10-tetracarboxylic dianhydride; charge transfer compounds for electronics, optoelectronics and photonic applications; chemical intermediates | BASF AKTIENGESELLSCHAFT (DE) | 2008-01-24 | — | — | US | disclosed |
| WO-2007128774-A1 | METHOD FOR PRODUCING ORGANIC FIELD-EFFECT TRANSISTORS | BASF SE (DE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259475-A1 | METHOD FOR PRODUCING ORGANIC FIELD-EFFECT TRANSISTORS | BASF AKTIENGESELLSCHAFT (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070191639-A1 | Optically active 1-Aryl-2-fluoro-substituted ethylamine and method for producing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2007-08-16 | — | — | US | disclosed |
| WO-2007074137-A1 | NAPHTHALENETETRACARBOXYLIC ACID DERIVATIVES AND THEIR USE AS SEMICONDUCTORS | BASF SE (DE) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007061677-A2 | SPIROLACTAM ARYL CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006127550-A1 | PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006127550-A1 | PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324865-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | QDPR, SIRT5, PDXK | DPP4 5/4885F2 15/4885HTR2A 1003/4885 |
| US-11548871-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | LPAR3, LPAR1, LPAR2 | DPP4 774/4885F2 2448/4885HTR2A 2420/4885 |
| US-20080017850-A1 | applying n-type organic semiconducting compound 1,6,7,12-Tetrachloro-N,N'-benzyl-perylene-3,9; 11,12-tetracarboxylic diimide or 1,6,7,12-tetrachloroperylen-3,9; 9,10-tetracarboxylic dianhydride; charge transfer compounds for electronics, optoelectronics and photonic applications; chemical intermediates | POF1B, NR2C2, NR2E1 | DPP4 2238/4885F2 2128/4885HTR2A 2546/4885 |
| US-20070191639-A1 | Optically active 1-Aryl-2-fluoro-substituted ethylamine and method for producing same | NAT1, AFF1, ALKBH1 | DPP4 2106/4885F2 1215/4885HTR2A 196/4885 |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR3, LPAR1, LPAR2 | DPP4 774/4885F2 2448/4885HTR2A 2420/4885 |
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | SSTR4, SSTR3, SSTR5 | DPP4 561/4885F2 2870/4885HTR2A 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.